The relevant information included in this section is exactly as published on the website of the National Securities Market Commission (CNMV)
Filter results
| Date | Title | Content | |
|---|---|---|---|
| 7/11/2019 | Information on P&L | ROVI releases the press release related to the first nine months 2019 financial results | |
| 7/11/2019 | Information on P&L | ROVI releases the first nine months 2019 results presentation | |
| 3/10/2019 | Liquidity contracts and specialists | Liquidity contract: transactions conducted in the third quarter of 2019 | |
| 5/09/2019 | Others on business performance and financial information | The Company informs about the construction of a second heparin plant in Granada | |
| 30/07/2019 | Information on P&L | ROVI releases the first half 2019 results presentation | |
| 30/07/2019 | Information on P&L | ROVI releases the press release related to the first half 2019 financial results | |
| 5/07/2019 | R&D: new licenses, patents and registered trademarks | ROVI announces completion of the Clinical Trial Program that will support the application for marketing authorization for Doria® for the treatment of schizophrenia. | |
| 2/07/2019 | Liquidity contracts and specialists | Liquidity contract: transactions conducted in the second quarter of 2019 | |
| 26/06/2019 | Información sobre dividendos | The Company informs about the dividends payment | |
| 12/06/2019 | Convocatorias y acuerdos de Juntas y Asambleas generales | ROVI releases the information related to its General Shareholders Meeting |